Raffaele Colombo/LinkedIn
Apr 21, 2025, 10:22
Raffaele Colombo: Positive topline results from DESTINY-Breast09!
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“Positive topline results from DESTINY-Breast09!
Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in lPFS compared to taxane, trastuzumab and pertuzumab (THP).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 26, 2025, 10:50
Jul 26, 2025, 10:41
Jul 26, 2025, 10:29
Jul 26, 2025, 09:59
Jul 26, 2025, 09:45
Jul 26, 2025, 09:09
Jul 26, 2025, 08:40
Jul 26, 2025, 08:13